Ignite Creation Date:
2024-05-05 @ 4:59 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00367315
Status:
COMPLETED
Last Update Posted:
2012-05-21
First Post:
2006-08-18
Brief Title:
Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis OA
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A 13-week Multicenter Randomized Double-blind Double-dummy Placebo-controlled Parallel Trial of 2 Different Dose Regimens of Lumiracoxib 100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od in Patients With Primary Knee Osteoarthritis Using Celecoxib 200 mg od as a Comparator
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the efficacy and safety of using lumiracoxib in the treatment of patients with knee osteoarthritis OA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None